Hyperpolarized 2-oxoglutarate as metabolic agent in mr

Pernille Rose Jensen; Magnus Karlsson; Mathilde Hauge Lerche; Claudia   Cabella; Lara  Caminiti; Sonia Colombo Serra; Luigi Miragoli; Luisa Poggi; Luca Venturi; Fabio Tedoldi

Hyperpolarized 2-oxoglutarate as metabolic agent in mr

Pernille Rose Jensen (Inventor), Magnus Karlsson (Inventor), Mathilde Hauge Lerche (Inventor), Claudia Cabella (Inventor), Lara Caminiti (Inventor), Sonia Colombo Serra (Inventor), Luigi Miragoli (Inventor), Luisa Poggi (Inventor), Luca Venturi (Inventor), Fabio Tedoldi (Inventor)

Department of Electrical Engineering

Research output: Patent

94 Downloads (Pure)

Abstract

Hyperpolarized 1-13C-2-oxoglutarate as contrast agent in13C Magnetic Resonance diagnostic technique (13C-MRI) for use in the diagnosis of cancer. In particular, upon administration of said 1-13C-2-oxoglutarate, signals of 1-13C-glutamate are detected. More in particular, different MR signals from13C nuclei are detected and compared, said comparison being useful to determine a difference between tumor and non-tumor tissues, to determine the aggressiveness of a tumor or the efficacy of an anti-tumor therapy

Original language	English
IPC	A61K 49/ 10 A I
Patent number	EP2911704
Filing date	02/09/2015
Country	International Bureau of the World Intellectual Property Organization (WIPO)
Priority date	24/10/2013
Priority number	WO2013EP72269
Publication status	Published - 2 Sep 2015

Bibliographical note

Also published as: WO2014064194 (A1) US2015273086 (A1)

Access to Document

EP2911704A1Final published version, 15.6 KB

Fingerprint Dive into the research topics of 'Hyperpolarized 2-oxoglutarate as metabolic agent in mr'. Together they form a unique fingerprint.

Cite this

Jensen, Pernille Rose (Inventor) ; Karlsson, Magnus (Inventor) ; Lerche, Mathilde Hauge (Inventor) ; Cabella, Claudia (Inventor) ; Caminiti, Lara (Inventor) ; Colombo Serra, Sonia (Inventor) ; Miragoli, Luigi (Inventor) ; Poggi, Luisa (Inventor) ; Venturi , Luca (Inventor) ; Tedoldi, Fabio (Inventor). / Hyperpolarized 2-oxoglutarate as metabolic agent in mr. Patent No.: EP2911704. Sep 02, 2015.

@misc{87503ab976ad4f9fbf56bcb6265e7263,

title = "Hyperpolarized 2-oxoglutarate as metabolic agent in mr",

abstract = "Hyperpolarized 1-13C-2-oxoglutarate as contrast agent in13C Magnetic Resonance diagnostic technique (13C-MRI) for use in the diagnosis of cancer. In particular, upon administration of said 1-13C-2-oxoglutarate, signals of 1-13C-glutamate are detected. More in particular, different MR signals from13C nuclei are detected and compared, said comparison being useful to determine a difference between tumor and non-tumor tissues, to determine the aggressiveness of a tumor or the efficacy of an anti-tumor therapy",

author = "Jensen, {Pernille Rose} and Magnus Karlsson and Lerche, {Mathilde Hauge} and Claudia Cabella and Lara Caminiti and {Colombo Serra}, Sonia and Luigi Miragoli and Luisa Poggi and Luca Venturi and Fabio Tedoldi",

note = "Also published as: WO2014064194 (A1) US2015273086 (A1) ; EP2911704; A61K 49/ 10 A I",

year = "2015",

month = sep,

day = "2",

language = "English",

type = "Patent",

}

Hyperpolarized 2-oxoglutarate as metabolic agent in mr. / Jensen, Pernille Rose (Inventor); Karlsson, Magnus (Inventor); Lerche, Mathilde Hauge (Inventor); Cabella, Claudia (Inventor); Caminiti, Lara (Inventor); Colombo Serra, Sonia (Inventor); Miragoli, Luigi (Inventor); Poggi, Luisa (Inventor); Venturi , Luca (Inventor); Tedoldi, Fabio (Inventor).

Patent No.: EP2911704. Sep 02, 2015.

Research output: Patent

TY - PAT

T1 - Hyperpolarized 2-oxoglutarate as metabolic agent in mr

AU - Jensen, Pernille Rose

AU - Karlsson, Magnus

AU - Lerche, Mathilde Hauge

AU - Cabella, Claudia

AU - Caminiti, Lara

AU - Colombo Serra, Sonia

AU - Miragoli, Luigi

AU - Poggi, Luisa

AU - Venturi , Luca

AU - Tedoldi, Fabio

N1 - Also published as: WO2014064194 (A1) US2015273086 (A1)

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Hyperpolarized 1-13C-2-oxoglutarate as contrast agent in13C Magnetic Resonance diagnostic technique (13C-MRI) for use in the diagnosis of cancer. In particular, upon administration of said 1-13C-2-oxoglutarate, signals of 1-13C-glutamate are detected. More in particular, different MR signals from13C nuclei are detected and compared, said comparison being useful to determine a difference between tumor and non-tumor tissues, to determine the aggressiveness of a tumor or the efficacy of an anti-tumor therapy

AB - Hyperpolarized 1-13C-2-oxoglutarate as contrast agent in13C Magnetic Resonance diagnostic technique (13C-MRI) for use in the diagnosis of cancer. In particular, upon administration of said 1-13C-2-oxoglutarate, signals of 1-13C-glutamate are detected. More in particular, different MR signals from13C nuclei are detected and compared, said comparison being useful to determine a difference between tumor and non-tumor tissues, to determine the aggressiveness of a tumor or the efficacy of an anti-tumor therapy

M3 - Patent

M1 - EP2911704

Y2 - 2015/09/02

ER -